贝伐-话题@MedSci

#贝伐#

228篇内容 | 4151人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477097, encodeId=092314e7097b0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗在NSCLC领域的主要研究, objectType=article, longId=220754, objectId=9edd220e54ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9edd220e54ec, replyNumber=0, likeNumber=30, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9edd220e54ec, moduleTitle=贝伐珠单抗在NSCLC领域的主要研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9edd220e54ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477096, encodeId=c95b14e7096f1, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗在肺癌驱动基因阴性的治疗, objectType=article, longId=220747, objectId=11d1220e47cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11d1220e47cc, replyNumber=0, likeNumber=34, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11d1220e47cc, moduleTitle=贝伐珠单抗在肺癌驱动基因阴性的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11d1220e47cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477090, encodeId=632514e709080, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=68, createdTime=2021-10-02, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477089, encodeId=cecd14e70898a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=67, createdTime=2021-09-16, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477088, encodeId=376914e70885c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, objectType=article, longId=216300, objectId=4bad2163009e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bad2163009e, replyNumber=0, likeNumber=88, createdTime=2021-08-27, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bad2163009e, moduleTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bad2163009e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477087, encodeId=8ef414e70872a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, objectType=article, longId=216224, objectId=35e921622426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e921622426, replyNumber=0, likeNumber=90, createdTime=2021-08-25, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e921622426, moduleTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e921622426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477086, encodeId=d5bb14e7086c3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒, objectType=article, longId=215197, objectId=d41921519e47, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d41921519e47, replyNumber=0, likeNumber=82, createdTime=2021-08-04, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d41921519e47, moduleTitle=Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d41921519e47)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=67, createdTime=2021-07-30, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477084, encodeId=ed1614e70844a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=67, createdTime=2021-07-26, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477083, encodeId=895314e7083bb, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, objectType=article, longId=214192, objectId=a0972141922d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0972141922d, replyNumber=0, likeNumber=83, createdTime=2021-07-15, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0972141922d, moduleTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0972141922d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477082, encodeId=299b14e70823d, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=45, createdTime=2021-07-03, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477081, encodeId=22f514e708181, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准, objectType=article, longId=213464, objectId=e1b42134644e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b42134644e, replyNumber=0, likeNumber=68, createdTime=2021-06-30, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b42134644e, moduleTitle=信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b42134644e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477080, encodeId=ddf914e708098, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=42, createdTime=2021-06-28, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477079, encodeId=1d5c14e7079d1, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, objectType=article, longId=212817, objectId=1b8121281e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8121281e7b, replyNumber=0, likeNumber=105, createdTime=2021-06-18, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8121281e7b, moduleTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8121281e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477078, encodeId=1ac814e707870, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=31, createdTime=2021-06-11, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477077, encodeId=eacc14e707779, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=212455, objectId=f416212455b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f416212455b8, replyNumber=0, likeNumber=58, createdTime=2021-06-09, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f416212455b8, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f416212455b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477076, encodeId=882f14e7076aa, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, objectType=article, longId=212406, objectId=efa62124062e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa62124062e, replyNumber=0, likeNumber=89, createdTime=2021-06-08, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa62124062e, moduleTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa62124062e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477075, encodeId=6a5e14e707500, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Angiogenesis：可预测贝伐单抗诱发高血压风险的血浆生物标志物, objectType=article, longId=212087, objectId=a67821208e9d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a67821208e9d, replyNumber=0, likeNumber=73, createdTime=2021-06-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a67821208e9d, moduleTitle=Angiogenesis：可预测贝伐单抗诱发高血压风险的血浆生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a67821208e9d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477074, encodeId=713614e70743c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量, objectType=article, longId=211990, objectId=cb0b211990bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb0b211990bb, replyNumber=0, likeNumber=83, createdTime=2021-05-30, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb0b211990bb, moduleTitle=Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb0b211990bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477073, encodeId=941814e70731c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, objectType=article, longId=211519, objectId=7c45211519d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c45211519d9, replyNumber=0, likeNumber=57, createdTime=2021-05-20, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c45211519d9, moduleTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c45211519d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗在NSCLC领域的主要研究

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗在肺癌驱动基因阴性的治疗

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2021-10-02

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期

2021-09-16

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗

2021-08-27

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！

2021-08-25

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒

2021-08-04

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2021-07-30

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

2021-07-26

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析

2021-07-15

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-07-03

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准

2021-06-30

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-06-28

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！

2021-06-18

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2021-06-11

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-06-09

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益

2021-06-08

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Angiogenesis：可预测贝伐单抗诱发高血压风险的血浆生物标志物

2021-06-01

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lancet oncol：阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量

2021-05-30

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性

2021-05-20

科室
- - 订阅+
  - 更多科室
工具
服务